Tag Archives: non-alcoholic fatty liver disease

Novartis and Pfizer announce clinical development agreement for the treatment of NASH

Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development portfolio in non-viral liver diseases, including NASH There are currently no … Read the full press release